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Abstract
Women with pathologic levels of antiphospholipid antibodies (aPL) are at high risk for
recurrent pregnancy loss and preeclampsia. Despite treatment with low molecular weight
heparin (LMWH), either alone or with low dose aspirin (ASA), the incidence of late-term
complications remains high for these patients. aPL recognizing β 2 glycoprotein I (β2GPI)
are particularly harmful during pregnancy as they target the placenta causing insufficient
spiral artery transformation and inflammation, giving rise to obstetric APS. There have
been extensive studies into the mechanisms by which aPL affect the placental trophoblast
which constitutively synthesizes and expresses β2GPI. However, aPL specific for β2GPI
can also bind to maternal uterine endothelial cells, but much less is known about the
impact aPL have on the maternal side of the maternal-fetal interface. This study sought to
characterize the effects of anti-β2GPI aPL on human endometrial endothelial cells
(HEECs); the role of toll-like receptor-4 (TLR4) in the mechanism of aPL-HEEC
interactions; and the influence of LMWH and ASA on aPL-mediated HEEC responses
using in vitro culture systems. aPL, but not control IgG, significantly increased HEEC
secretion of pro-angiogenic vascular endothelial growth factor (VEGF) and placental
growth factor (PlGF); increased anti-angiogenic soluble fms-like tyrosine kinase
receptor-1 (sFlt-1); inhibited basal secretion of the chemokines monocyte
chemoattractant protein-1 (MCP-1), granulocyte colony-stimulating factor (G-CSF) and
growth related oncogene- α (GRO-α); and impaired angiogenesis. The aPL-triggered
inhibition of HEEC MCP-1 was mediated by activation of TLR4. LMWH and ASA,
alone and in combination, exacerbated the aPL-induced changes in the HEEC angiogenic
factor and chemokine profile. There was no reversal of the aPL-inhibition of HEEC
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angiogenesis by either single or combination therapy. In conclusion, HEECs produce
chemokines necessary for normal trophoblast invasion, immune cell recruitment, and
spiral artery remodeling. By aPL inhibiting HEEC chemokine secretion and promoting
sFlt-1 release, the uterine endothelium may contribute to impaired placentation and
vascular transformation in obstetric APS. Combination LMWH and ASA may further
contribute to this endothelium dysfunction in women with obstetric APS.

Published in part:
Quao ZC, Tong M, Bryce E, Guller S, Chamley LW, Abrahams VM. Low molecular
weight heparin and aspirin exacerbate human endometrial endothelial cell responses to
antiphospholipid antibodies. Am J Reprod Immunol. 2017;e12785.
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Introduction
Diagnosis of APS
Antiphospholipid syndrome (APS) is an acquired autoimmune disease in which
patients have circulating autoantibodies called antiphospholipid antibodies that aberrantly
recognize certain phospholipid-binding proteins leading to a hypercoaguable state and
increased risk of recurrent venous and arterial thrombosis. These patients have increased
risk of stroke and myocardial infarction, among other complications and disease
manifestations. In women, APS causes increased risk of recurrent fetal loss in addition to
complications such as hypertension and preeclampsia, preterm labor, premature rupture
of membranes, and intrauterine growth restriction [1, 2].
The Sapporo Classification Criteria Guidelines for diagnosis of this disease
include both clinical and laboratory criteria. Criteria for clinical diagnosis rely on patient
history while laboratory criteria relies on the presence of certain antibodies. The current
clinical criteria include: arterial, venous, or small vessel thrombosis, in any organ or
tissue; and pregnancy morbidity consisting of: 1) one or more unexplained deaths of a
morphologically normal fetus at or beyond the 10th week of gestation; or 2) one or more
premature births of morphologically normal neonate at or before the 34th week of
gestation because of severe preeclampsia, eclampsia or severe placental insufficiency; or
3) three or more unexplained consecutive spontaneous abortions before the 10th week of
gestation. The updated laboratory criteria include: medium to high serum titers (greater
than 40 GPL/MPL or > 99th percentile) of IgG or IgM isotype of anticardiolipin on two
or more occasions, at least 12 weeks apart measured by standardized ELISA; lupus
anticoagulant present in plasma on two or more occasions at least 12 weeks apart
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detected by the guidelines of the International Society of Thrombosis and Haemostasis;
and anti-beta 2 glycoprotein-I (anti-β2GPI) antibody of IgG or IgM isotype in serum or
plasma (>99th percentile), also measured at 12 week intervals [1].
Given the fact that diagnosis of this disease in women oftentimes relies on
repeated pregnancy loss, it may require years of symptoms and/or several episodes of
high-risk gestation before patients receive proper treatment. During pregnancy, women
with APS are at further increased risk of late-term complications in addition to the
systemic cardiovascular risks of the disease. Furthermore, women with anti-β2GPI
antibodies are at highest risk of fetal loss and late-term complications because the
placental trophoblast synthesizes and expresses β2GPI, making this organ a specific target
for aPL [3-6].

Antiphospholipid antibodies in APS
There are several antibodies that are pathogenic in APS, but, as previously stated, the
most deleterious in pregnancy are anti-β2GPI aPL. Anti-β2GPI antibodies are a
heterogeneous group of polyclonal antibodies, which bind to different epitopes of β2GPI,
a glycosylated, anionic phospholipid-binding glycoprotein that belongs to the
complement control protein (CCP) superfamily. This protein’s function is still a subject
of study, but its structure is known. β2GPI has five CCP domains. The first four domains
have the regular, conserved sequences, but the fifth domain is different. These additional
amino acids in domain V are responsible for a unique feature of this CCP domain,
because they constitute a large positively charged patch that determines the affinity for
anionic phospholipids [7]. Domain V is thought to interact with various cell surface
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receptors such as apoER2, Toll-like receptors (TLRs), and other negatively charged
molecules such as heparin, DNA, low density oxidized lipoproteins and annexin II [8]. In
the serum, β2GPI is circular with domain V binding to the cell surface causing a
conformational change, thus exposing the other CCP domains. β2GPI localizes to the
syncytiotrophoblast cells that are in direct contact with maternal blood [3, 9] as well as
the invasive cytotrophoblast and extravillous trophoblast cells. In addition, serum β2GPI
can also localizes to human endometrial endothelial cells, which the invasive trophoblasts
invade and replace during normal spiral artery transformation [10]. Thus, both the
trophoblast and endometrial endothelial cells are a target for anti-β2GPI aPL. Studies
have shown that different epitopes on β2GPI are recognized by different aPL, with only
some of these populations having pathological significance in aPL [11-13], though there
is debate between which domains and epitopes are more pathogenic than others.
Depending on the epitopes to which they bind, aPL can have varying functional and
pathogenic effects on the cells they attack [14]. aPL recognizing β2GPI do not only bind
trophoblasts, but can also affect the maternal side of the uteroplacental interface by
binding directly to the endometrial endothelial cells [15-17]. Animal models have
supported a role for anti-β2GPI aPL in the pathogenesis of pregnancy failure and
complications. Immunization of animals with β2GPI or passive transfer of aPL to mice
lead to pregnancy complications often seen in APS, namely fetal demise and IUGR, as
well as reduced litter size and fetal resorption equivalent to implantation failure and
pregnancy loss in humans [18, 19].
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Normal Placentation
To form a normal placenta, a fertilized egg, a zygote, undergoes a process of cleavages
into a collection of cells called a blastula and differentiates into what is called a
blastocyst. The blastocyst contains a blastocoel, or fluid-filled blastocyst cavity, which
contains an inner mass of cells called the embryoblast, that will form the fetus. The
blastocyst also contains an outer layer of cells called the trophoectoderm, which forms
the placenta. The blastocyst interacts with and implants into the maternal decidua. After
contact and adhesion of the blastocyst to the uterine epithelium, trophoblast cells
differentiate into a fusion lineage, the syncytiotrophoblast, and an invasive lineage, the
cytotrophoblast. The invasive lineage of trophoblasts penetrate deep into the maternal
decidua, differentiating into extravillous trophoblasts, through to the smooth muscle layer
called the myometrium. This lineage of trophoblasts is also responsible for invading the
uterine spiral arteries where they differentiate into endovascular trophoblast. Eventually
they interact with and replace the endometrial endothelial cells in the spiral arteries order
to form large caliber vessels for a well-rooted placenta with a large-volume blood supply
in a process called vascular transformation [20].
In order for this placentation to occur, endothelial and decidual cells must
adequately promote trophoblast invasion, immune cell recruitment, and spiral artery
remodeling via the secretion and excretion of factors, cytokines, and chemokines, to
establish the adequate placentation and vascular development needed for a healthy
pregnancy. Normal placentation relies on successful vascular transformation and
angiogenesis which leads to the expansion in size and number of vasculature at the
maternal-fetal interface and of the placenta and decidua. Extravillous trophoblasts invade
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the spiral arteries disrupting the smooth muscle cells, and interacting with and ultimately
replacing the endothelial cells. This transforms them into high flow, low resistance
vessels necessary to support the fetus through the term of pregnancy. If this process is
aberrant and there is a failure of trophoblast contact, adhesion, invasion, and vascular
transformation, pregnancy complications associated with insufficient placentation may
result. In obstetric APS, preeclampsia is the most common complication associated with
inadequate placentation. There are many proposed mechanisms for this observed
pathology.

Preeclampsia and abnormal placentation in APS
Impaired angiogenesis and vascular development/remodeling.
Gestational hypertension and preeclampsia are likely due to insufficient placentation and
poor spiral artery transformation. Since APS is a syndrome which affects the caliber of
placentation, obstetric APS shares many features of preeclampsia. Clinical signs of
inadequate placentation are placental hypoperfusion and ischemia which cause increased
resistance in placental vessels and vascular endothelial stress. Clinical signs of
preeclampsia in the mother are characterized by the onset of high blood pressure and
often a significant amount of protein in the urine in addition to end-organ damage as a
result of the hypertension after 20 weeks of pregnancy. In severe cases, preeclampsia can
lead to eclampsia, which is characterized by maternal seizures and can progress to more
severe liver, kidney, and retinal damage, systemic edema, and thrombocytopenia [21].
There are many potential causes of preeclampsia, but it is clear that some sort of placental
injury or insults create the hypertensive phenotype of the disease and immediate delivery
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of the fetus and placenta is the therapy of choice. Preeclampsia presents risks to the
mother and fetus as immediate delivery due to potential end-organ damage of a
potentially premature fetus represents a significant deviation from normal uncomplicated
pregnancy. Premature births are at risk of cerebral hemorrhage and inadequate lung
development. Women with preeclampsia are also at risk of further cardiovascular
complications after delivery [22].
Preeclampsia is hypothesized to be as result of early aberrations in placental
vascular remodeling, though it often presents as a late-term complication. Altered
vascular reactivity, impaired trophoblast invasion, increased oxidative stress,
deregulation of vasoactive substances, immune response and deregulation of angiogenic
factor secretion have all been attributed to causing preeclampsia [21, 23, 24]. Similarly in
obstetric APS, inadequate placentation and deregulation of angiogenic factor secretion
has been shown to cause preeclampsia [25-27]. Furthermore, mouse models have
suggested that two placental anti-angiogenic proteins, circulating sFlt1 and soluble
endoglin (sEndoglin), play a causal role in the pathogenesis of preeclampsia [28, 29].
sEndoglin is a truncated, soluble form of Eng, which antagonizes transforming growth
factor-β (TGF-β). TGF-β has many functions, but it is also a potent angiogenic factor and
upregulates VEGF, in early gestational trophoblasts [29]. sFlt1 is a soluble, truncated
variant of the VEGF receptor, Flt1. sFlt1 acts as a potent antagonist to VEGF and PlGF.
VEGF and PlGF are both pro-angiogenic factors [30]. Placental growth factor is proangiogenic as it enhances the activity of VEGF by competitively binding to the VEGF
receptor-1, allowing VEGF to bind then to VEGF receptor-2 which has stronger tyrosine
kinase activity [31]. Studies have also shown that heterodimers of VEGF and PlGF act as
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pro-angiogenic factors [32, 33]. Both VEGF and PlGF are made by the placenta and
circulate in high concentration during pregnancy. There is an observed downregulation of
circulating vascular endothelial growth factor, VEGF, and placental growth factor, PlGF
and a marked increase in sFlt-1 and sEndoglin [21] in preeclampsia. Furthermore, a study
by Levine et al. showed that rising circulating serum levels of sEndoglin and ratios of
sFlt1:PlGF predict the onset of preeclampsia in pregnant patients [34]. In patients with
APS, Cuadrado et al. demonstrated that VEGF may stimulate monocyte tissue factor
expression through its receptor, Flt-1, contributing to the proinflammatory-prothrombotic
phenotype of obstetric APS patients [25].

Reduced cytotrophoblast invasiveness
sFlt1 has also been shown to decrease cytotrophoblast invasiveness in vitro [35].
Reduced cytotrophoblast invasion is a shared characteristic between preeclampsia and
obstetric APS. Di Simone et al. found that direct action of polyclonal patient derived aPL
on cytotrophoblasts has been associated with reduced placental human chorionic
gonadotropin (hCG) and placental placental lactogen (hPL) secretion and a complete
block of trophoblast invasiveness and adhesion [36]. Similar findings were replicated by
Katsuragawa et al. which found that monoclonal aPLs decrease trophoblast hCG and hPL
secretion and block trophoblast invasiveness [37].
Trophoblast adhesion is also negatively affected by the trophoblast. Zhou et al.
found that in normal placental development the cytotrophoblasts assume an endothelial
phenotype in a process called vascular mimicry, or pseudovasculogenesis, by
downregulating the expression of adhesion molecules characteristic of their epithelial cell
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origin and adopting an endothelial cell surface adhesion phenotype [38]. In preeclampsia,
cytotrophoblasts do not undergo switching of cell-surface molecules and are unable to
invade the myometrial spiral arteries [39]. In obstetric APS, Di Simone et al. were able to
demonstrate that patient derived aPLs are able to change the expression of trophoblast
adhesion molecules [40]. Furthermore, they were able to show that aPL are able to
mediate trophoblast gonadotropin secretion and reduced invasion through direct binding
to adhered β2GPI. Our group also found two domain V anti-β2GPI Abs (ID2 and IIC5)
inhibit first trimester trophoblast cell migration by downregulating IL-6 production. This
inhibition leads to decreased signal transducer and activator of transcription 3 (STAT3)
activity. By using a blocking anti-IL-6R antibody, IL-6 was shown to be partly
responsible for trophoblast cells’ spontaneous migratory capacity [41].

Dysfunctional immune cell recruitment and inflammation
Although systemic APS is known and studied as a pro-thrombotic disorder,
obstetric APS has been increasingly been shown to be a disorder of inflammation.
Previously, the prevailing hypothesis was that, similar to the pathophysiology of stroke,
myocardial infarction, and venous thromboembolism in patients with systemic APS, the
pathophysiology of recurrent pregnancy loss in pregnant patient with APS was due to
clotting at the maternal-fetal interface [42-44]. This hypothesis was supported by the
apparent success of the anti-thrombotic heparin combined with anti-platelet aspirin at
increasing live birth weight. However, histological studies of placentas with APS confirm
more prevalent inflammation rather than intraplacental thrombosis at the maternal-fetal
interface including inflammatory cytokine expression, immune cell infiltration and
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complement deposition [6, 45, 46]. Sebire et al. found that defective trophoblast invasion
and spiral artery transformation was more often seen in aPL positive placentas, while
there was no significant increase in thrombotic events between aPL positive and aPL
negative placentas [47]. Similarly, Stone et al. showed that the placentas of these patients
become infiltrated with inflammatory immune cells such as macrophages [46]. Salmon
and Girardi showed using in vivo mouse models that aPL activate both classical and
alternative complement pathways. Complement activation propagates injury to the fetus
by recruiting inflammatory neutrophils, inducing their expression of tissue factor (TF),
and overwhelming the trophoblast’s normal inhibitory mechanisms [48]. This also
potentiates inflammation in the decidua and leading to miscarriages [49]. Thus, while
immune cells are necessary for promoting trophoblast recruitment, spiral artery
remodeling, angiogenesis, and thus, successful implantation [50, 51], unregulated
inflammation can cause defective placentation.

Mechanisms of placental inflammation in obstetric APS
It is hypothesized that anti-B2GPI aPL bind to membrane-bound β2GPI
complexed with anionic transmembrane receptors and intracellular ligands on the surface
of cells such as monocytes, trophoblasts, endothelial cells, and others. In this way, aPL
are able to effect mechanisms of innate immunity, trophoblast proliferation, and cellular
regulation of homeostasis [52]. However, the mechanisms of thrombotic and nonthrombotic aPL-mediated cellular changes are unclear, especially in the case of obstetric
APS which is seen as a subset of APS and may have distinct pathogenic mechanisms.
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Alone, one of β2GPI’s alleged functions is as a component of innate immunity.
Agar et al. showed that binding of β2GPI to LPS caused a conformational change in
β2GPI that led to binding of the β2GPI-LPS complex to monocytes and ultimately
clearance of this complex [53]. β2GPI, once it is bound to aPL, has also been shown to
bind and augment its interaction with transmembrane and intracellular ligands similarly
to microbial and murine studies have shown that bacteria partially homologous with
β2GPI structure are able to induce the generation of pathogenic anti-β2GPI antibodies
along with some APS manifestations [54, 55]. Anti- β2GPI antibodies have been shown
to interact with many innate immune receptors such as toll-like receptors 2 and 4, most
commonly, which recognize and bind bacterial LPS, in addition to annexin A2, an
extracellular receptor for plasminogen and tissue type plasminogen activator, and
apolipoprotein E receptor-2 (apoER2), involved in endocytosis of ligands and signal
transduction [7, 56]. Thus, microbial mimicry may be the mechanism by which aPL are
able to alter cellular response, not by inducing thrombosis through the complement
cascade or interfering with thrombin and antithrombin III, as has previously been
hypothesized [57].
Toll-like receptors have increasingly been associated with increased inflammatory
cytokine release in systemic APS and more recently in obstetric APS [58]. In systemic
APS, TLRs have been found to facilitate activation of monocytes and endothelial cells by
aPL in vitro and in vivo [59, 60]. And a recent study by Laplante et al. showed that aPLmediated effects on the arterial model of thrombosis require TLR4 activation [61]. Since
TLR4 has been established as a necessary receptor in LPS signaling receptor in mice
studies [62] and has been found to activate endothelial cells in APS [55], homology
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between LPS and other microbes is seen as the mechanism by which aPL induce an
inflammatory immune response. This theory was further supported in a study by Sorice et
al., where it was demonstrated that in monocytes, anti-β2GPI binding Abs causes β2GPI
and TLR4 to co-localize in lipid rafts and induce interleukin-1 receptor associated kinase
(IRAK) phosphorylation and nuclear factor-κB (NF-κB) translocation and a subsequent
release of tumor necrosis factor-α (TNF-α) and TF [63]. TNF-α is a central regulator of
inflammation and tissue factor is a pro-coagulant. Tissue factor has also been implicated
in aPL mouse studies where TF blockade prevented aPL antibody–induced inflammation
and pregnancy loss. TF expression in neutrophils contributes to respiratory burst and
subsequent trophoblast injury and pregnancy loss induced by aPL antibodies [64].
In the trophoblast, our group has shown that aPL induces a pro-inflammatory and
anti-angiogenic response in first trimester trophoblast via the TLR4/MyD88 pathway
[65]. Through TLR4 activation, anti-β2GPI antibodies trigger increased trophoblast
secretion of IL-8, MCP-1, GRO-α, and IL-1β. IL-8 is a potent neutrophil chemoattractant
cytokine produced by several cells. In vivo, intracutaneous application of IL-8 induces
local exudation and a massive, long-lasting accumulation of neutrophils [66]. IL-1β is a
potent pro-inflammatory cytokine important in mediating host immune responses towards
infection [67]. Not only has IL-1β upregulation been associated with autoimmune disease
[68], but has also been associated with pre-eclampsia and pre-term birth [69, 70]. MCP-1
is a chemoattractant for human monocytes (which mature into macrophages) and may
also activate cellular functions related to host defense [50, 71]. GRO-α is expressed on
macrophages, neutrophils, and epithelial cells and has chemotactic properties for

16

neutrophils and is important in promoting successful spiral artery transformation and
implantation [51].

Effect of aPL on endothelial cells in obstetric APS
The effect of aPL on the trophoblast has been well studied, however, much about
the action of aPL on HEECs, the cells which trophoblasts bind to and replace during
spiral artery transformation, is still unclear. Most aPL-endothelial interactions in
pregnancy and placentas have been studied using fetus-derived human endothelial cells
from umbilical veins (HUVECs) as a model for systemic vascular events in APS. Similar
to findings in the trophoblast [65], aPL recognizing β2GPI are able to activate the
TLR4/MyD88 signaling pathway in HUVECs [72, 73] and induce an inflammatory
cytokine/chemokine response [74]. Another study by Raschi et al. also using HUVECs
showed that both human anti-β2GPI IgM monoclonal antibodies and polyclonal affinitypurified anti-β2GPI IgG antibodies induce a pro-inflammatory phenotype in endothelial
cells, most likely via the involvement of TLRs and activation of the MyD88 pathway
[55]. Di Simone et al. have investigated the influence of aPL on human endometrial
endothelial cells and confirmed a direct effect of aPL on maternal cells. A 2010 report
found that human polyclonal aPL significantly decreased the number and length of
tubules formed by HEECs and reduced newly formed vessels in a murine model. aPL
also significantly reduces VEGF and matrix metalloproteinase (MMP) production and
suppressed ΝFκΒ DNA binding activity[16]. In a 2012 study by the same group, lowmolecular weight heparin mitigated the aPL inhibited effects on ΝFκΒ and STAT-3
activity, VEGF secretion and MMP activity in HEECs [15]. Finally, Di Simone et al.

17

found that a synthetic peptide (that shares an amino acid sequence with domain V of
β2GPI) competes with aPL binding to HEECs to restore aPL-mediated effects on
angiogenesis [17]. These studies indicate that aPL have a specific effect in HEECs and
further investigation is needed to define the spectrum of ways angiogenesis and
endometrial activity are altered by different aPL.

Preeclampsia, APS, and the use of Therapeutic Low molecular Weight Heparin and
Aspirin
In the absence of aPL, heparin, both LMWH and unfractionated (UFH), and low dose
ASA, have been proposed as potential prophylaxis for preeclampsia and other
hypertensive disorders like HELLP syndrome in addition to being used to prevent
unexplained fetal loss [75]. Although LMWH (and UFH) and low dose ASA have long
been prescribed empirically, their effectiveness has only been demonstrated in cases of
obstetric APS [76, 77]. However, LMWH and low dose ASA have also been suggested in
second-trimester pregnancy loss [78] and in pregnancies deemed to be at high risk for
poor perinatal outcome [79, 80].
Pregnant women with APS are routinely treated with LMWH, either alone or in
combination with acetyl-salicylic acid (aspirin, ASA), as soon as possible in pregnancy
and 6 weeks post-partum, with practice varying amongst physicians and with regard to
patient disease severity and history [81]. In women with aPL, without a history of
previous clot, or pregnancy loss, low dose ASA alone is deemed sufficient. In women
with a history of previous thromboembolism, therapeutic doses of unfractionated heparin
or LMWH are recommended. In women with medium titers of anti-cardiolipin
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antibodies, anti-β2GPI antibodies or lupus anticoagulant, and who have a history of 2 or
more early pregnancy losses, fetal deaths or >1 preterm births, low dose ASA along with
prophylactic doses of UFH or LMWH is the standard of care [82]. However, studies
regarding each medication’s effectiveness for preventing RPL in the setting of aPL are
controversial [83, 84]. Heparin has been shown in previous studies to increase incidence
of live birth weight and reduced rates of fetal loss. A study by Girardi et al. showed that
heparin prevents fetal loss by inhibiting complement and not through its anticoagulant
effects [85]. On the other hand, there is evidence that heparin increases the release of
sFlt-1 and impairs VEGF signaling in placental villi, thereby potentially damaging and
inhibiting placentation [86]. However, LMWH treatment also resulted in increased
release of PlGF, whereas sEndoglin release remained unaltered and VEGF was
undetected. Similarly, a study in 11 preeclamptic women in the third trimester showed
that administration of LMWH resulted in a 26% mean increase in serum sFlt1 though this
antiangiogenic effect was partially counterbalanced by a smaller increase in PlGF levels,
resulting in a less pronounced difference in the ratio between the two concentrations [87].
Additionally, heparin does not reverse aPL-mediated changes in trophoblast angiogenic
factor secretion but instead promotes sFlt-1 release [88]. However, LMWH can dampen
aPL-induced trophoblast inflammation and complement activation, as shown by Girardi
et al. in a murine model of APS-mediated pregnancy losses [85]. It must be noted that
both UFH and LMWH are prescribed and studied, but LMWH has improved
pharmacokinetics and bioavailability and is less likely to cause heparin-induced
thrombocytopenia. It is also demonstrably more successful in some studies than
unfractionated heparin [81], though the difference in pregnancy outcome between UFH
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and LMWH in APS is also controversial [89]. UFH has also been shown to reduce
trophoblast invasion in extravillous trophoblasts [90]. Aspirin is used as an adjunct
medication, but has since been shown to have no significant beneficial effect and may no
longer be indicated [91]. However, combination low molecular weight heparin and
aspirin are still administered for obstetric APS and recent studies contend that early
administration of aspirin in the first trimester is more beneficial than 2nd or 3rd trimester
administration due to potential benefit in early stages of implantation [63] and beneficial
effects of LMWH may be through mechanisms distinct of its anticoagulant properties.

Summary
The impact aPL have on trophoblast function and the mechanisms involved has
been well studied. Much about the action of aPL on these human endometrial endothelial
cells (HEECs) is still unclear. Most aPL-endothelial interactions in pregnancy and
placentas have been studied using fetus-derived HUVECs as a model for systemic
vascular events in APS. However, to better understand the placental endothelium and the
nature of the maternal decidua’s interaction with aPL, an additional set of fetally-derived
cells are not as appropriate to detect key differences and, perhaps, similarities between
aPL-trophoblast and aPL-endometrium interactions. The objective of this study was to
elucidate the influence that domain I and V anti-β GPI aPL have on the maternal uterine
2

vasculature using HEECs, and to investigate the role of TLR4. This study also sought to
evaluate the current therapeutic strategy of LMWH and ASA in counteracting any
influences aPL had on HEEC function.
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Hypothesis
In previous studies, aPL recognizing domain V of β2GPI have been shown to induce
elevated levels of pro-inflammatory cytokines and chemokines [65]; inhibit spontaneous
trophoblast migration[41]; and modulate trophoblast angiogenic factor secretion [47].
The inflammatory response of trophoblasts to aPL has been confirmed to be mediated by
innate immune receptor TLR4. Similarly, researchers have studied the effect of aPL on
systemic APS using HUVECs. This research also found that TLR4 may be influencing
HUVEC response to aPL. Finally, there is conflicting evidence as to whether domain I or
domain V anti-β2GPI antibodies are more deleterious in APS pregnancies [73, 92]. Thus,
my hypothesis is that aPL recognizing domain V, but not domain I induce a proinflammatory and anti-angiogenic profile in HEECs, disrupting their tube formation,
via activation of TLR4. Furthermore, I hypothesize that LMWH and ASA do not
attenuate aPL effects on HEECs.

Specific Aims
1. To characterize the effect of aPL recognizing domain I or domain V of β2GPI
on HEEC cytokine, chemokine, and angiogenic factor secretion and tube
formation.
2. To determine the role of TLR4 in HEEC responses to aPL.
3. To determine the effect of LMWH and/or ASA on HEEC responses to aPL.
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Materials and Methods
Reagents
Sterile low molecular weight heparin (LMWH) (enoxaparin sodium injection;
100mg/ml), was purchased from Aventis Pharmaceuticals, Inc. (Bridgewater, NJ).
Acetyl-salicylic acid (ASA) was obtained from Sigma-Aldrich (St. Louis, MO),
reconstituted in ethanol, and filter-sterilized prior to use. Ethanol alone was included as a
vehicle control for ASA. The TLR4 antagonist, LPS-RS (Lipopolysaccharide isolated
from Rhodobacter sphaeroides), was purchased from Invivogen (San Diego, CA).

Human endothelial cells
The human endometrial endothelial cells (HEECs) used in this study were originally
isolated from the microvascular of cycling endometrium of multiple women, and all
stages of cycles were pooled. The primary cells were characterized to express a range of
adhesion molecules and endothelial markers, and to form endothelial tubes when seeded
in Matrigel. Subsequently these cells were telomerase immortalized and have been
characterized to express the same markers and function as the primary cells [93-97].

Human umbilical vein endothelial cells
Primary human umbilical vein endothelial cells (HUVECs) were obtained from Yale
University's tissue culture core laboratory, courtesy of Dr. Seth Guller [98]. Cell culture
was performed as previously described [93, 96] and both cell types were cultured in
Endothelial Basal Medium-2 (EBM-2) supplemented with 2% fetal bovine serum (FBS)
(Lonza; Allendale, NJ).
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Antiphospholipid antibodies
This study used two mouse IgG1 anti-human β2GPI monoclonal antibodies (mAbs), ID2
and IIC5. Like patient-derived polyclonal aPL, both IIC5 and ID2 bind β2GPI in a similar
manner to human aPL when they are immobilized on negatively charged surfaces such as
phospholipids, cardiolipin, phosphatidyl serine or irradiated polystyrene [99]. The
binding of both ID2 and IIC5 to β2GPI is inhibited by patient-derived aPL, and both
antibodies have been shown to alter trophoblast function similarly to patient-derived
polyclonal aPL-IgG [100] and polyclonal IgG aPL recognizing β2GPI [65, 88] upon
binding to first trimester extravillous trophoblast cells, whereas a mouse IgG1 isotype
control has no effect [65, 88]. IIC5 and ID2 react specifically with an epitope within
domain V of β2GPI, which may be more important than domain I binding aPL for
pregnancy morbidity in APS patients [101]. IIC5 also has pronounced lupus
anticoagulant activity and thus represents a triple positive aPL [102]. This study also used
one anti-human β2GPI Ab (P1-117) that reacts specifically with an epitope within domain
I of β2GPI [103, 104]. Mouse IgG1 clone 107.3 (BD Biosciences) was used as an isotype
control.

Angiogenic factor and chemokine studies
HEECs (5x105) or HUVECs (5x105) were plated in 60mm tissue culture plates pre-coated
with 2% gelatin in EBM-2 media supplemented with 2% FBS. The next day the media
was replaced and the cells treated. HEECs or HUVECs were treated for 72hrs with either
no treatment (NT), aPL (60µg/ml) or control IgG (60µg/ml) to establish the baseline
effect of aPL. The aPL dose was determined by preliminary dose response experiments
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(data not shown) and are similar to other studies [17]. To study the role of TLR4, HEECs
were treated for 72hrs with NT or aPL in the presence of either media or LPS-RS
(10µg/mL). To study the effect of current therapeutics on HEEC responses to aPL, cells
were treated for 72hrs with NT, LMWH (10µg/ml), ASA (10µg/ml) or both LMWH and
ASA (each at 10µg/ml) in the presence of either media or aPL (60µg/ml). The
concentrations of ASA and LMWH used in this study were based on a previous study,
and equivalent to low dose medications used in the clinical setting [105]. After treatment,
cell-free supernatants were collected and stored at -80°C. Supernatants were then
measured by ELISA and/or multiplex analysis. The pro-angiogenic factors: vascular
endothelial growth factor (VEGF) and placental growth factor (PlGF); and the antiangiogenic factors: soluble FMS-like tyrosine kinase-1 (sFlt-1) and soluble endoglin
(sEndoglin) were measured by ELISA (R&D Systems; Minneapolis, MN). The
chemokines, monocyte chemoattractant protein 1 (MCP-1/CCL2) and granulocyte
colony-stimulating factor (G-CSF/CSF3) were also measured by ELISA (R&D Systems).
Multiplex analysis (Bio-Rad, Hercules, CA, USA) was performed for the following
analytes as previously described [106]: interleukin (IL)-1β; IL-6; IL-8 (CXCL8); IL-10;
IL-12 (p70); IL-17; growth-regulated oncogene-alpha (GRO-α/CXCL1); granulocyte
macrophage-colony stimulating factor (GM-CSF/CSF2); interferon gamma (IFNγ); IFN γ
inducible protein 10 (IP-10/CXCL10); macrophage inflammatory protein 1 alpha (MIP1α/CCL3); MIP-1β (CCL4); Regulated on Activation, Normal T Cell Expressed and
Secreted (RANTES/CCL5) and tumor necrosis factor alpha (TNFα). ELISA was used for
subsequent measurements of IL-8 (Assay Designs/Enzo Life Sciences; Farmingdale, NY,
USA) and GRO-α (R&D Systems).
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Angiogenesis assay
An endothelial tube formation assay was used to measure angiogenesis as previously
described [15, 16]. HEECs (5x104) were seeded into 24-well tissue culture plates over
undiluted reduced growth factor Matrigel (BD-Biosciences; San Jose, CA) with or
without aPL (60µg/ml) or control IgG (60µg/ml). In separate experiments, HEECs were
plated with NT, LMWH (10µg/ml), ASA (10µg/ml) or both LMWH and ASA (each at
10µg/ml) in the presence of either media or aPL (60µg/ml). Following an 8hr incubation,
the formation of vessel tube-like structures was monitored by light microscopy (CarlZeiss Observer Z1). Four fields per well were recorded using OpenLab software (Perkin
Elmer). The number of tubes per field were counted manually by two individuals,
independently, and the two sets of data for each field were averaged.

Statistical analysis
Each experiment was performed at least three times. All analyses were performed at least
in duplicate. All data are reported as mean ± standard error of the mean (SEM) of pooled
experiments. Statistical significance was set at p<0.05 and determined using Prism
Software (Graphpad, Inc; La Jolla, CA). For normally distributed data, significance was
determined using either one-way analysis of variance (ANOVA) for multiple
comparisons or a t-test. For data not normally distributed, significance was determined
using a non-parametric multiple comparison test for multiple comparisons or the
wilcoxon matched-pairs signed rank test.
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RESULTS
Domain V aPL, IIC5, alter HEEC angiogenic factor and chemokine secretion

Figure 1. Effect of aPL on HEEC angiogenic factor and chemokine secretion. HEECs
were treated with no treatment (NT), aPL (IIC5), or control IgG. Data are pooled from 9
independent experiments. Bar charts show secreted levels of VEGF; PlGF; sFlt-1;
sEndoglin; MCP-1; G-CSF; GRO-α; IL-8; and GM-CSF as determined by ELISA and
multiplex analysis. *p<0.05 relative to the NT control.

The first objective of this study was to measure the effects of the anti-β2GPI aPL, IIC5,
that recognizes domain V of β2GPI on the HEEC angiogenic and cytokine/chemokine
factor profile. Compared to the no treatment (NT) control, aPL significantly increased
HEEC secretion of: pro-angiogenic VEGF by 20.5±8.7-fold; pro-angiogenic PlGF by
3.7±0.8-fold; and anti-angiogenic sFlt-1 by 2.4±0.4-fold (Figure 1). The IgG control had
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no significant effect on HEEC secretion of VEGF, PlGF, or sFlt-1 (Figure 1). Neither
aPL, nor the IgG control had any significant effect on HEEC production of sEndoglin
compared tp the NT control (Figure 1). Treatment of HEECs with aPL significantly
reduced basal MCP-1 secretion by 44.8±7.3%; G-CSF by 31.0±12.8%; and GRO-α by
37.5±4.6% when compared to the NT control. The IgG control had no significant effect
on HEEC secretion of MCP-1, G-CSF, or GRO-α (Figure 1). Neither aPL, nor the IgG
control, had any significant effect on HEEC production of IL-8 or GM-CSF compared to
the NT control (Figure 1), and all other factors tested by multiplex were below the assay's
detection limit (data not shown).
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Domain V aPL, ID2, and Domain I aPL, PI-117, do not alter HEEC angiogenic factor
and chemokine secretion

Figure 2. Effect of Domain V Abs, ID2, and Domain I Ab, PI-117 on HEEC angiogenic
factor and chemokine secretion. HEECs were treated with no treatment (NT), ID2, PI117 or control IgG. Data are pooled from 9 independent experiments. Bar charts show
secreted levels of sFlt-1; PlGF; VEGF; MCP-1; G-CSF; GRO-α; sEndoglin; IL-8; and
GM-CSF as determined by ELISA and multiplex analysis. *p<0.05 relative to the NT
control.

The next objective was to determine whether the domain I aPL, PI-117, or domain V
aPL, ID2, also influenced HEEC angiogenic and cytokine/chemokine factor profile.
Compared to the no treatment (NT) control, ID2, PI-117, and IgG control had no
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significant effect on HEEC secretion of sFlt-1, PlGF, VEGF, MCP-1, G-CSF, GROα,
sEndoglin, GM-CSF, or IL-8 (Figure 2).

Domain V aPL, IIC5 induce a distinct angiogenic factor and chemokine profile in
HUVECs

Figure 3. Effect of IIC5 aPL on HUVEC angiogenic factor and chemokine secretion.
HEECs were treated with no treatment (NT), aPL, or control IgG. Data are pooled from 3
independent experiments. Barcharts show secreted levels of VEGF; PlGF; sFlt-1;
sEndoglin; MCP-1; G-CSF; GRO-α; IL-8; and GM-CSF as determined by ELISA.
*p<0.05 relative to the NT control.
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Since HUVECs are commonly used as a model for the study of the endothelium in APS,
(27-30), we sought to determine if their response to aPL recognizing β2GPI was similar to
the HEECs. Similar to the HEECs, aPL significantly increased HUVEC secretion of proangiogenic VEGF by 80.4±11.6-fold; pro-angiogenic PlGF by 12.1±0.3-fold; and antiangiogenic sFlt-1 by 2.0±0.0-fold when compared to the NT control (Figure 3). The IgG
control had no significant effect on HUVEC secretion of VEGF, PlGF or sFlt-1 (Figure
3). In contrast to the HEECs, aPL significantly increased HUVEC secretion of the antiangiogenic sEndoglin by 1.6±0.2-fold compared to the NT control, while the IgG control
had no effect (Figure 3). The aPL-modulated chemokine profile was also distinct.
Compared to the NT control, aPL significantly increased HUVEC secretion of G-CSF by
1.8±0.2-fold and significantly reduced GM-CSF secretion by 28.0 ±20.4%, while the IgG
control had no significant effect (Figure 3). Neither aPL, nor the IgG control, had any
significant effect on HUVEC production of MCP-1, GRO-α or IL-8 compared to the NT
control (Figure 3).
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Domain V aPL, ID2, and Domain I aPL, PI-117, do not induce a distinct angiogenic
factor and chemokine profile in HUVECs

Figure 4. Effect of Domain V Ab, ID2, and Domain I Ab, PI-117 on HUVEC angiogenic
factor and chemokine secretion. HEECs were treated with no treatment (NT), ID2, PI117 or control IgG. Data are pooled from 9 independent experiments. Bar charts show
secreted levels of sFlt-1; PlGF; VEGF; MCP-1; G-CSF; GRO-α; sEndoglin; IL-8; and
GM-CSF as determined by ELISA and multiplex analysis. *p<0.05 relative to the NT
control.

Again, since HUVECs are commonly used as a model for the study of the endothelium in
APS, we sought to determine if their response to ID2 and PI-117 Abs recognizing domain
V and domain I β2GPI epitopes, respectively, were similar to the HEECs. Compared to
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the no treatment (NT) control, ID2, PI-117, and IgG control had no significant effect on
HEEC secretion of sFlt-1, PlGF, VEGF, MCP-1, G-CSF, GRO-, sEndoglin, GM-CSF, or
IL-8 (Figure 4).

aPL inhibition of HEEC MCP-1 secretion is mediated by TLR4

Figure 5. Effect of TLR4 inhibition on aPL-induced HEEC angiogenic factor and
chemokine secretion. HEECs were treated with no treatment (NT) or aPL (IIC5) in the
presence of media or LPS-RS. Supernatants were measured by ELISA for: VEGF; PlGF;
sFlt-1; MCP-1; G-CSF; and GRO-α. Data are pooled from 3 independent experiments.
*p<0.05 relative to the matching NT control for each condition (media or LPS-RS) unless
otherwise indicated.
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Having established the HEEC angiogenic and chemokine profile induced by the domain
V aPL, IIC5, the next objective was to investigate the mechanism involved by blocking
TLR4 function using the antagonist, LPS-RS. aPL-induced secretion of VEGF, PlGF and
sFlt-1 was not reversed by the presence of LPS-RS, although aPL-induced PlGF was
slightly yet significantly increased by 1.1±0.1-fold (Figure 5). While LPS-RS
significantly increased basal MCP-1 levels by 1.3±0.0-fold, in the presence of aPL, MCP1 levels were significantly increased by 2.4±0.1-fold, bringing levels back to baseline.
Thus, the presence of LPS-RS, completely reversed the inhibition of HEEC MCP-1
secretion induced by aPL (Figure 5). Although LPS-RS slightly, yet significantly,
increased basal G-CSF levels by 1.2±0.0-fold, there was no significant effect on the
ability of aPL to inhibit HEEC secretion of either G-CSF or GRO-α (Figure 5).
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Effect of LMWH and ASA on HEEC angiogenic factor and chemokine secretion in the
presence and absence of aPL

Figure 6. Effect of ASA and LMWH on HEEC aPL-induced HEEC angiogenic factor and
chemokine secretion. HEECs were treated no treatment (NT), ASA, LMWH or both
(LMWH + ASA) in the presence of media or aPL. Supernatants were measured by
ELISA for: VEGF; PlGF; sFlt-1; MCP-1; G-CSF; and GRO-α. Data are pooled from 3
independent experiments. *p<0.05 relative to the NT/media control unless otherwise
indicated.

Since our understanding of the actions of LMWH and ASA in obstetric APS are
incomplete, the effects of these therapies, alone and in combination, on HEEC function in
the presence and absence of aPL were investigated. The findings are summarized in
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Table 1. As already determined, treatment of HEECs with the domain V aPL, IIC5,
significantly increased VEGF, PlGF, and sFlt-1; and significantly inhibited MCP-1, GCSF and GRO-α secretion compared to the NT/media control (Figure 6).

LMWH and ASA, either alone or in combination, had no effect on basal VEGF secretion.
When compared to the NT/media control ASA alone significantly reduced basal PlGF by
19.8±3.8% and G-CSF by 16.4±4.3%. Compared to the NT/media control, LMWH
alone, or in combination with ASA, significantly increased basal levels of HEEC sFlt-1
by 2.3±0.1-fold and 2.1±0.1-fold, respectively; increased basal levels of G-CSF by
1.3±0.1-fold and 1.2±0.1-fold, respectively; and decreased basal levels of MCP-1 by
31.3±5.0% and 31.3±6.5%, respectively. Compared to the NT/media control, LMWH
alone significantly decreased basal levels of HEEC GRO-α secretion by 9.7±3.1%
(Figure 6 & Table 1). Ethanol alone was run as a control for ASA and had no effect on
any of the factors tested (data not shown), with the exception of GRO-α which was
significantly inhibited by 25.9±8.1%. Thus, ASA, either alone or in combination with
LMWH, was excluded from the GRO-α analysis.

LMWH alone significantly reduced the aPL-induced upregulation of HEEC VEGF
secretion by 24.6±13.5%. However ASA, either alone or in combination, had no effect on
VEGF production in the presence of aPL. LMWH in combination with ASA significantly
augmented the aPL-induced upregulation of HEEC PlGF by 1.1±0.0-fold. However
LMWH alone or ASA alone had no effect on PlGF production in the presence of aPL.
LMWH either alone, or in combination with ASA, significantly augmented the aPL-
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induced upregulation of HEEC sFlt-1 by 1.4±0.1-fold and 1.6s±0.1-fold, respectively,
while ASA alone had no effect. LMWH and ASA, either alone or in combination, had no
effect on the ability of aPL to reduce HEEC MCP-1 secretion. ASA either alone, or in
combination with LMWH significantly and further reduced the aPL-mediated inhibition
of HEEC G-CSF by 25.6±4.8% and 17.4±8.9%, respectively, while LMWH alone had no
effect. LMWH alone further reduced the aPL-mediated inhibition of HEEC GRO-α
secretion by 14.4±5.0% (Figure 6 & Table 1).

Table 1

Table 1: Summary of the effects of ASA and LMWH on HEEC angiogenic factor and
chemokine secretion in the presence and absence of aPL.
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aPL inhibit HEEC angiogenesis

Figure 7. Effect of aPL on HEEC tube formation. HEECs were seeded on Matrigelcoated plates and treated with no treatment (NT), the domain V aPL, IIC5, or control IgG
control. After 8hrs, tube-like vessels were imaged and quantitative analysis performed.
Images are from one representative field of one representative experiment (magnification
10X). Bar chart shows the number of tubes counted per field and pooled from 5
independent experiments. *p<0.05 relative to the NT control.

The next objective was to determine whether aPL affected vascular development. For
this, an angiogenesis assay was utilized in which the formation of HEEC vessel tube-like
structures in Matrigel was measured. When compared to the NT control, the domain V
aPL, IIC5, significantly reduced the number of HEEC tubes formed by 19.1±9.9%, while
the IgG control had no significant effect (Figure 7).
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Effect of LMWH and ASA on HEEC angiogenesis in the presence and absence of aPL

Figure 8. Effect of ASA and LMWH on HEEC tube formation in the presence and
absence of aPL. HEECs were seeded on Matrigel-coated plates and treated with no
treatment (NT), ASA, LMWH or both (LMWH + ASA) in the presence of media or the
domain V aPL, IIC5. After 8hrs, tube-like vessels were imaged and quantified. Images
are from one representative field of one representative experiment (magnification 10X).
Bar chart shows the number of tubes counted per field and pooled from 4 independent
experiments. *p<0.05 relative to the NT/media control unless otherwise indicated.

When compared to the NT/media control, HEEC tube formation was significantly
reduced by 27.9±15.1% in the presence of ASA alone, by 30.2±14.2% in the presence of
LMWH alone, and by 24.1±14.5% in the presence of combination LMWH and ASA
(Figure 8). The ethanol control had no effect on the basal HEEC tube formation (Data not
shown). As already determined, treatment of HEECs with aPL significantly inhibited
HEEC tube formation by 26.3±9.1% compared to the NT/media control. LMWH and
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ASA, either alone or in combination, had no additional effect on the numbers of HEEC
tubes formed in the presence of aPL (Figure 8).

DISCUSSION
Obstetric APS, once thought of as a thrombotic disease, is now known to be
inflammatory in origin and associated with placental insufficiency and reduced vascular
development and remodeling [6]. One major way in which aPL negatively impact
pregnancy is by targeting the placenta, via alteration of trophoblast function [107-109].
During pregnancy, aPL recognizing β2GPI can also affect the maternal side of the
interface by binding directly to the uterine endothelium [4, 15-17] which provides the
scaffolding upon which trophoblast cells transform the maternal spiral arteries [10].
However, little is known about how aPL influence the function of these human
endometrial endothelial cells (HEECs). Furthermore, little is known about the impact the
current therapeutics for obstetric APS have on HEEC function. Herein, we report that an
aPL recognizing domain V of β2GPI modulates HEEC angiogenic factor and chemokine
production, in part through TLR4 activation, and disrupts angiogenesis. Furthermore,
LMWH and ASA, in general, exacerbate rather than protect against these aPL-mediated
changes in HEEC function.
Previous studies found that aPL inhibits HEEC VEGF secretion; STAT3
phosphorylation; NFκB activity; and their ability to form vessel tube-like structures in
vitro [107-109]. However, little else was known about their responses to aPL or the
mechanisms involved. What these studies did highlight was a role for domain V of β2GPI
as the peptide TIFI, that shares homology with the aPL-binding site of domain V, blocked
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these responses [17]. In our current study, using an aPL that binds to domain V of β2GPI,
[101] we found that HEEC pro-angiogenic (VEGF, PlGF) and anti-angiogenic factor
production (sFlt-1) was augmented, while basal chemokine secretion (MCP-1, G-CSF,
GRO-α) was inhibited. In addition, HEEC angiogenesis was inhibited. While antiangiogenic sFlt-1 is associated with promoting hypertension and proteinuria in
preeclampsia [110] there is also evidence that sFlt-1 contributes to poor placentation by
impairing endothelial function, impacting uterine vessel remodeling [111, 112] and
blocking the action of VEGF and PlGF, which promote trophoblast differentiation and
invasion [113] and angiogenesis [114-116]. Thus, although HEEC production of proangiogenic VEGF and PIGF was also increased, the elevated sFlt-1 response may
contribute to the impaired HEEC angiogenesis that we, and others [15-17], have
observed. Moreover, the aPL-induced upregulation of HEEC VEGF production may
drive the sFlt-1 response [116]. The differences in our studies demonstrating elevated
HEEC VEGF secretion in response to aPL, while Di Simone’s group showed a reduction
in this pro-angiogenic factor, may be explained by differences in culture conditions or in
the use of our monoclonal domain V aPL compared to their use of polyclonal aPL [15,
16].
In this study, we also found that aPL suppressed HEEC secretion of chemokines
that promote trophoblast invasion (G-CSF) [117], and recruit macrophages and natural
killer cells (MCP-1, GRO-α) that are necessary for normal spiral artery remodeling [50,
51, 118, 119]. These data suggest that aPL may contribute to the shallow trophoblast
invasion and disrupted spiral artery transformation seen in obstetric APS by directly
impacting the uterine endothelium, in addition to targeting the placental trophoblast [41,

41

120]. Furthermore, we observed that under basal conditions, in general, HEECs produced
higher levels of chemokines compared to the angiogenic factors. This may reflect the
normal function of uterine endothelial cells in playing an important role in immune cell
recruitment at the maternal-fetal interface for successful vascular remodeling [121]. Our
studies also highlight that being of fetal origin, and generating a distinct angiogenic and
chemokine profile in response to aPL, HUVECs may not be the best model for studying
the endothelium in either systemic or obstetric APS.
A role for TLR4 has been demonstrated in aPL-mediated thrombosis [58, 61] and
in aPL-mediated trophoblast inflammation [65]. In studies using HUVECs, β2GPI
interacts directly with TLR4 and mediates aPL-induced endothelial cell activation [55,
72, 73, 122]. HEECs express functional TLRs, including TLR4 [97]. In this current
study, TLR4 was found to mediate the aPL-induced suppression of HEEC MCP-1
secretion, but was not involved in any of the other responses tested, suggesting a role for
additional cell surface receptors that aPL may recruit. These could include TLR2 [59] or
ApoER2 [123].
Finally, our studies confronted the debate amongst domain specificity and aPL
pathogenicity. Domain V ID2 and IIC5 have previously been shown to mediate changes
in trophoblast secretion [92] and PI-117 has demonstrated lupus anticoagulant activity
[104]. However, the reaction of HEECs and HUVECs, both endothelial cells, show that
specific epitopes, even more specific than the general domain to which aPL bind, indicate
what types of aPL are more deleterious to endothelial cells.
LMWH is commonly used as an anticoagulant treatment in systemic APS, and
early initiation of aspirin (prior to 16 weeks of gestation) is thought to be beneficial for

42

fetal development [124]. Both therapies are given empirically to women with recurrent
miscarriage, whether it is due to APS or not [75, 125, 126]. In women with aPL, while
LMWH, either alone or in combination with aspirin, has been shown to decrease rates of
fetal loss, results are conflicting [83, 89, 91, 127, 128]. Furthermore, despite treatment,
women with APS continue to have high rates of late gestational complications [84, 125,
129, 130]. Given these controversies, we sought to elucidate the action of LMWH and
ASA either alone or in combination on HEEC function in the absence and presence of
aPL.
In the absence of aPL, LMWH and ASA, alone and in combination, induced
potentially detrimental angiogenic and chemokine effects on HEECs, somewhat akin to
aPL treatment. Similar to what has been found in the trophoblast [88, 105, 107, 131].
LMWH induced the release of sFlt-1, confirming this observation in endothelial cells
from other sources [132]. LMWH also reduced HEEC angiogenesis, potentially as a
consequence of the overwhelming sFlt-1 release [111, 112], which again has been
observed in other endothelial cell types [132]. Interestingly, ASA had a similar effect by
inhibiting HEEC tube formation, an observation also seen in HUVECs [114, 115]. As a
result, combination of LMWH and ASA increased HEEC sFlt-1 release and limited
angiogenesis. Both single and combination therapies also reduced basal HEEC
chemokine production.
This may be because LMWH can act through non-thrombotic pathways, by
inhibiting inflammation [65, 85, 105] and ASA is an anti-inflammatory agent [133, 134].
In the context of aPL, LMWH alone further augmented aPL-induced HEEC sFlt-1
release, further reduced GRO-α secretion, and reduced aPL-induced VEGF, while ASA
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alone further reduced HEEC G-CSF secretion. In combination, LMWH and ASA further
augmented aPL-induced HEEC sFlt-1 and PlGF release, and further reduced G-CSF
secretion. Thus, the net effect of LMWH and ASA was the exacerbation of aPL-induced
changes in the HEEC angiogenic factor and chemokine profile. Additionally, there was
no reversal of the aPL inhibition of HEEC angiogenesis by either single or combination
therapy.
In summary, HEECs produce a number of chemokines and pro-angiogenic factors
that may promote trophoblast invasion, immune cell recruitment, and spiral artery
remodeling, to establish the adequate placentation and vascular development needed for a
healthy pregnancy. An aPL recognizing domain V of β2GPI dysregulates this HEEC
angiogenic factor and chemokine profile, and limit angiogenesis. Thus, the uterine
endothelium may contribute to impaired placentation and vascular transformation seen in
women with obstetric APS. LMWH and ASA, either alone or in combination, may
further contribute to endothelial dysfunction in the setting of aPL, which may explain the
inability of current therapies to prevent adverse pregnancy outcomes in women with
APS.
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